Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
2011

Testing New CMV Inhibitors with a Special Virus

publication Evidence: high

Author Information

Author(s): He Ran, Sandford Gordon, Hayward Gary S, Burns William H, Posner Gary H, Forman Michael, Arav-Boger Ravit

Primary Institution: Johns Hopkins University School of Medicine

Hypothesis

Can recombinant luciferase-expressing human cytomegalovirus (CMV) be used to evaluate CMV inhibitors effectively?

Conclusion

The pp28-luciferase reporter system is a rapid and sensitive method for screening anti-CMV compounds.

Supporting Evidence

  • The pp28-luciferase virus showed a wider dynamic range of luciferase expression.
  • Luciferase expression correlated highly with plaque reduction and real-time PCR results.
  • The assay can be performed rapidly, making it suitable for high-throughput screening.

Takeaway

Researchers created a special virus that glows to help find new medicines to fight a common virus that can make people very sick.

Methodology

The study involved constructing recombinant CMV viruses expressing luciferase and testing their ability to indicate the effectiveness of antiviral compounds.

Limitations

The study may not account for all variables affecting CMV replication and drug efficacy.

Digital Object Identifier (DOI)

10.1186/1743-422X-8-40

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication